glp-1 for bulimia Neurobiological Mechanisms and Therapeutic Potential of Glucagon-like Peptide-1 Receptor Agonists in Binge Eating Disorder: A Narrative Review The rapid rise of GLP-1

Description

[1] [2] Additionally, when used with insulin or sulfonylureas, hypoglycemia may occur, potentially causing adrenergic symptoms including palpitations or chest discomfort

Additionally, patients should have regular thyroid function monitoring, as weight loss itself can sometimes necessitate adjustments to levothyroxine dosing

As off-label use continues to expand, particularly among patients with obesity or insulin resistance, our findings suggest GLP-1based therapies may warrant consideration as an adjunct to insulin in carefully selected patients. Advertisement Advertisement New service for patients with diabetes will make annual screening more convenient Association revises criteria for the diagnosis and resolution of severe conditions What to consider in the management of euglycemic DKA Less than 50% of patients with diabetes get appropriate ophthalmic screening through primary care referrals Familiarity will enhance its accessibility for patients with diabetes New study counters earlier findings linking drugs with eye disease Study highlights the value of quantitative ultra-widefield angiography Longevity in healthcare, personal experiences may provide caregivers with false sense of confidence

While the close relation between GLP-1 and insulin signalling is undoubtedly important in cognition, it is crucial to highlight that beyond this mechanism, GLP-1R mimetics upregulated several neuroprotective growth factors such as: insulin-like growth factor 1 (IGF-1) (165), brain-derived neurotrophic factor (BDNF) (166), glia-derived neurotrophic factor (GDNF) (164), as well as vascular endothelial growth factor (VEGF) (157, 158)